Search Results - "Zauderer, M.G."

Interim Analysis of a Phase 2 Toxicity Study on Hemithoracic Pleural Intensity Modulated Radiation Therapy (IMRT) for Malignant Pleural Mesothelioma (MPM) by Rimner, A, Zauderer, M.G, Rosenzweig, K.E, Wu, A.J, Foster, A, Yorke, E, Rusch, V.W, Krug, L.M

Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

192P Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis by Moore, Z.R., Rimner, A., Lobaugh, S., Geyer, A., Gelblum, D.Y., Shepherd, A.F., Shaverdian, N., Wu, A.J., Chaft, J.E., Zauderer, M.G., Rudin, C.M., Vander Els, N., Chawla, M., Jones, D.R., Sopka, D.M., Mak, R., Liao, Z., Gomez, D.R., Zhang, Z., Paik, P.

Get full text

1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors by Morschhauser, F., McKay, P., Salles, G., Stacchiotti, S., Schwartz, G.K., Tilly, H., Zauderer, M.G., Fennell, D.A., Jones, R.L., Schöffski, P., Phillips, T., Chaidos, A., Villalobos, V., Demetri, G., Cote, G., Sierra, L., Yang, J., Slatcher, P., Agarwal, S., Gounder, M.

Get full text

Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study by Reckamp, K.L., Akerley, W., Calvo, E., Clarke, J., Edelman, M.J., He, K., Moreno, V., Neal, J.W., Owonikoko, T.K., Patel, J.D., Patel, S.P., Riess, J.W., Sacher, A.G., Turcotte, S., Villaruz, L.C., Zauderer, M.G., Farsaci, B., Skoura, N., Chisamore, M., Johnson, M.L.

Get full text

1590TiP - Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study by Reckamp, K.L., Akerley, W., Calvo, E., Clarke, J., Edelman, M.J., He, K., Moreno, V., Neal, J.W., Owonikoko, T.K., Patel, J.D., Patel, S.P., Riess, J.W., Sacher, A.G., Turcotte, S., Villaruz, L.C., Zauderer, M.G., Farsaci, B., Skoura, N., Chisamore, M., Johnson, M.L.

“…NY-ESO-1 and LAGE-1a are antigens expressed in several tumours, including non-small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells…”
Get full text